CH Biomedical

CH Biomedical is a medical technology company focused on developing and commercializing ventricular assist devices (VADs) for patients with end-stage heart failure. The company's core product, the CH-VAD, is an implantable, fully magnetically levitated left ventricular assist device (LVAD) that represents a significant advancement in cardiac support technology. By employing magnetic levitation, the device eliminates mechanical friction, thereby reducing blood trauma and the risk of pump-induced thrombosis. Headquartered in Suzhou, China, with a research facility in the United States, the company successfully obtained regulatory approval from China's NMPA in 2021. CH Biomedical aims to address the global shortage of donor hearts by providing a reliable, long-term mechanical alternative for circulatory support.